Page last updated: 2024-08-26

mci 9038 and Cerebral Hemorrhage

mci 9038 has been researched along with Cerebral Hemorrhage in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (57.14)	29.6817
2010's	6 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barreto, AD; Cai, C; Ford, GA; Grotta, JC; Pedroza, C; Rahbar, MH; Shen, L; Tyson, J	1
Barreto, AD; Berekashvili, K; Blackburn, S; Chen, PR; Dannenbaum, M; Grotta, JC; Misra, V; Shen, L; Soomro, J	1
Chen, JL; Chen, W; Fan, RM; Han, C; Jiao, S; Li, G; Wang, CM; Xia, XP; Yao, ST; Zeng, YC	1
Qu, F; Zhang, CD; Zhou, ZH	1
Alexandrov, AV; Balucani, C; Barlinn, K; Barreto, AD; Chen, Z; Demchuk, AM; Garami, Z; Gonzales, NR; Grotta, JC; Lee, J; Lyden, P; Martin-Schild, S; Mikulik, R; Pandurengan, R; Rahbar, MH; Savitz, SI; Shen, L; Sisson, A; Sugg, RM; Tsivgoulis, G; Wu, TC	1
Alexandrov, AV; Bavarsad Shahripour, R	1
Hoff, JT; Hua, Y; Keep, RF; Kitaoka, T; Xi, G	1
Hoff, JT; Hua, Y; Keep, RF; Kitaoka, T; Nagao, S; Xi, G	1
Fujisawa, H; Koizumi, H; Nagatsuna, T; Nomura, S; Suehiro, E; Suzuki, M	1
Akaike, A; Fujimoto, S; Katsuki, H; Kume, T	1
Alexandrov, AV; Baraniuk, S; Garami, Z; Gonzales, NR; Grotta, JC; Matherne, DE; Mikulik, R; Moyé, LA; Pary, JK; Shaltoni, HM; Shaw, SG; Sugg, RM; Uchino, K	1
Akaike, A; Fujimoto, S; Katsuki, H; Kume, T; Ohnishi, M; Takagi, M	1
Berens, KL; Brown, PM; Chopp, M; Lu, M; Morris, DC; Zhang, L; Zhang, ZG	1
Hamada, R; Matsuoka, H	1

Reviews

2 review(s) available for mci 9038 and Cerebral Hemorrhage

Article	Year
Ancillary approaches to plasminogen activators. Annals of the New York Academy of Sciences, 2012, Volume: 1268 Topics: Anticoagulants; Arginine; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Collateral Circulation; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hypothermia, Induced; Low-Level Light Therapy; Pipecolic Acids; Plasminogen Activators; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy; Vasodilator Agents	2012
Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? CNS drugs, 2002, Volume: 16, Issue:8 Topics: Antithrombins; Arginine; Brain; Brain Edema; Cerebral Hemorrhage; Humans; Neurons; Pilot Projects; Pipecolic Acids; Sulfonamides; Survival Rate; Thrombin; Treatment Outcome	2002

Article

Year

Ancillary approaches to plasminogen activators.

Annals of the New York Academy of Sciences, 2012, Volume: 1268

Topics: Anticoagulants; Arginine; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Collateral Circulation; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hypothermia, Induced; Low-Level Light Therapy; Pipecolic Acids; Plasminogen Activators; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy; Vasodilator Agents

2012

Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention?

CNS drugs, 2002, Volume: 16, Issue:8

Topics: Antithrombins; Arginine; Brain; Brain Edema; Cerebral Hemorrhage; Humans; Neurons; Pilot Projects; Pipecolic Acids; Sulfonamides; Survival Rate; Thrombin; Treatment Outcome

2002

Trials

2 trial(s) available for mci 9038 and Cerebral Hemorrhage

Article	Year
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke, 2017, Volume: 48, Issue:6 Topics: Aged; Aged, 80 and over; Antithrombins; Arginine; Brain Ischemia; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pipecolic Acids; Severity of Illness Index; Stroke; Sulfonamides; Tissue Plasminogen Activator	2017
Argatroban tPA stroke study: study design and results in the first treated cohort. Archives of neurology, 2006, Volume: 63, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Cerebral Hemorrhage; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pipecolic Acids; Prospective Studies; Recombinant Proteins; Research Design; Stroke; Sulfonamides; Tissue Plasminogen Activator; Treatment Outcome	2006

Article

Year

Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

Stroke, 2017, Volume: 48, Issue:6

Topics: Aged; Aged, 80 and over; Antithrombins; Arginine; Brain Ischemia; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pipecolic Acids; Severity of Illness Index; Stroke; Sulfonamides; Tissue Plasminogen Activator

2017

Argatroban tPA stroke study: study design and results in the first treated cohort.

Archives of neurology, 2006, Volume: 63, Issue:8

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Cerebral Hemorrhage; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pipecolic Acids; Prospective Studies; Recombinant Proteins; Research Design; Stroke; Sulfonamides; Tissue Plasminogen Activator; Treatment Outcome

2006

Other Studies

10 other study(ies) available for mci 9038 and Cerebral Hemorrhage

Article	Year
Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:12 Topics: Aged; Aged, 80 and over; Arginine; Cerebral Hemorrhage; Combined Modality Therapy; Drug Therapy, Combination; Endovascular Procedures; Feasibility Studies; Fibrinolytic Agents; Humans; Incidence; Middle Aged; Pipecolic Acids; Platelet Aggregation Inhibitors; Postoperative Complications; Stroke; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome	2018
Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clinical and experimental immunology, 2014, Volume: 175, Issue:2 Topics: Animals; Apoptosis; Arginine; Brain Edema; Cerebral Hemorrhage; Complement C5a; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Peptides, Cyclic; Pipecolic Acids; Platelet Aggregation Inhibitors; Receptor, Anaphylatoxin C5a; RNA, Messenger; Stroke; Sulfonamides; Tubulin	2014
Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage. Brain research bulletin, 2011, Oct-10, Volume: 86, Issue:3-4 Topics: Animals; Arginine; Blotting, Western; Body Water; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Female; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, PAR-1; Stereotaxic Techniques; Sulfonamides	2011
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke, 2012, Volume: 43, Issue:3 Topics: Aged; Anticoagulants; Antithrombins; Arginine; Brain Ischemia; Cerebral Arteries; Cerebral Hemorrhage; Cerebral Veins; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Stroke; Sulfonamides; Tissue Plasminogen Activator; Treatment Outcome; Ultrasonography, Doppler, Transcranial	2012
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke, 2002, Volume: 33, Issue:12 Topics: Animals; Antithrombins; Arginine; Brain; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hemoglobins; Infusions, Parenteral; Male; Microinjections; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Sulfonamides; Time Factors; Treatment Outcome; Water	2002
Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat. Acta neurochirurgica. Supplement, 2003, Volume: 86 Topics: Animals; Antithrombins; Arginine; Brain; Brain Edema; Cerebral Hemorrhage; Collagenases; Drug Administration Schedule; Hematoma; Injections; Injections, Intraperitoneal; Male; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides	2003
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 19, Issue:3 Topics: Animals; Anticoagulants; Arginine; Astrocytes; Brain Edema; Cerebral Hemorrhage; Hematoma; Male; Neutrophils; Pipecolic Acids; Rats; Rats, Wistar; Sulfonamides	2005
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures. Neurobiology of disease, 2006, Volume: 22, Issue:1 Topics: Animals; Anticoagulants; Apoptosis; Arginine; Brain Damage, Chronic; Caspase 3; Caspase Inhibitors; Caspases; Cerebral Cortex; Cerebral Hemorrhage; Corpus Striatum; MAP Kinase Signaling System; Nerve Degeneration; Organ Culture Techniques; Oxidative Stress; Phosphorylation; Pipecolic Acids; Protein Kinase C; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptor, PAR-1; src-Family Kinases; Sulfonamides; Thrombin; Time Factors	2006
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. Experimental neurology, 2007, Volume: 206, Issue:1 Topics: Animals; Arginine; Brain; Brain Damage, Chronic; Cell Death; Cerebral Hemorrhage; Cycloheximide; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gliosis; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Microglia; Nerve Degeneration; Neurons; Neuroprotective Agents; Pipecolic Acids; Platelet Aggregation Inhibitors; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin	2007
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke, 2001, Volume: 32, Issue:11 Topics: Animals; Antithrombins; Arginine; Brain Ischemia; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Fibrin; Incidence; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; Pipecolic Acids; Rats; Rats, Wistar; Recombinant Proteins; Stroke; Sulfonamides; Time Factors; Tissue Plasminogen Activator	2001